APhA Foundation Project IMPACT: Test and Treat manuscript now published
In Project IMPACT: Test and Treat , 15 community pharmacies throughout the country provided patients with access to test and treat services for COVID-19, strep, and flu. After completion of the test and discussion with the patient, the pharmacist could prescribe and dispense treatment in accordance with an established protocol as allowed by either their state board of pharmacy or in collaboration with a provider. The pharmacist provided counseling and follow-up scheduling as needed.
"This important work shows the exceptional outcomes that occur when pharmacists are involved," said
Project IMPACT: Test and Treat resulted in 88% of patients who were prescribed medication by the pharmacist receiving medication on the very same day. Researchers concluded that pharmacists are able to provide meaningful clinical benefits as well as cost savings to the patient and the health care system. Read the full manuscript here .
APhA Foundation would like to express sincere gratitude to the 15 community pharmacies that participated in this initiative. Financial and material support was provided by Abbott Laboratories.
To learn more about the APhA Foundation, visit aphafoundation.org.
View original content to download multimedia:https://www.prnewswire.com/news-releases/apha-foundation-project-impact-test-and-treat-manuscript-now-published-302535346.html
SOURCE American Pharmacists Association Foundation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Best Graphic Design Software for Print and Production Work (2026): CorelDRAW Recognized for Print-Friendly, Production-Ready Workflows by Better Business Advice
- BRX Coin to Launch on PancakeSwap August 9 With $500,000 Liquidity and 100% Locked LP
- Lennar Debuts Sutton and Hollis, Two New Home Collections at Valencia in the Santa Clarita Valley
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share